NEXTECH INVEST LTD
Q1 2024 Form 13-F
ZURICH
CIK 0001911010
· CRD 322629
· Exempt reporting adviser
$630.8M Reported Value Total
Exempt Reporting Adviser
nextechinvest.com
Source: Form ADV filed 2026-03-27
Reported value
$630.8M
Quarter over quarter
+12.6%
Holdings
12
Top-10 concentration
94.5%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $630.8M |
| Positions | 12 |
| Change in reported value | +17.5% |
| New positions | 2 |
| Exited positions | 1 |
| Position turnover | 23.1% |
| Top-10 concentration | 94.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2024 13F
Filed Feb 14, 2025
|
15 | $616.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $712.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $594.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $630.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
11 | $536.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
14 | $330.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
13 | $294.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
12 | $239.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
14 | $251.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $309.6M |
|
Q2 2022 13F
Filed Aug 1, 2022
|
14 | $296.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
14 | $350.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
11 | $379.6M |
Top 12 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $202.9M | 32.17% |
| 2 | ORIC ORIC PHARMACEUTICALS INC | $72.7M | 11.52% |
| 3 | TYRA TYRA BIOSCIENCES INC | $66.5M | 10.54% |
| 4 | CRGX CARGO THERAPEUTICS INC | $59.0M | 9.35% |
| 5 | ARVN ARVINAS INC | $58.1M | 9.22% |
| 6 | TNGX TANGO THERAPEUTICS INC | $43.9M | 6.97% |
| 7 | RLAY RELAY THERAPEUTICS INC | $31.9M | 5.06% |
| 8 | CGEM CULLINAN ONCOLOGY INC | $20.8M | 3.3% |
| 9 | SLN SILENCE THERAPEUTICS PLC | $20.6M | 3.26% |
| 10 | SPRY ARS PHARMACEUTICALS INC | $19.5M | 3.09% |
| 11 | BOLD BOUNDLESS BIO INC | $17.5M | 2.77% |
| 12 | MRSN MERSANA THERAPEUTICS INC | $17.3M | 2.74% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.